# OH2 Administered by Intratumoral Injection

> **NCT05954091** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Binhui Biopharmaceutical Co., Ltd.** · enrollment: 29 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** OH2 Injection

## Key facts

- **NCT ID:** NCT05954091
- **Lead sponsor:** Binhui Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05954091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05954091, "OH2 Administered by Intratumoral Injection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05954091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*